Amyloid Clearance Seen After 18 Months of Alzheimer's Care
A patient with early-stage Alzheimer’s saw amyloid protein disappear after 18 months of infusion therapy.
Updated on Oct. 21, 2026 in Alzheimer’s
A 75-year-old patient diagnosed with mild cognitive impairment caused by Alzheimer's recently showed no amyloid protein buildup on a brain PET scan. The result followed 18 months of infusion therapy using FDA-approved medications designed for early-stage Alzheimer's disease.
Why it matters
Amyloid clearance is the clinical goal of recently approved therapies aimed at slowing cognitive decline in early-stage Alzheimer's patients. Monitoring these treatments through imaging is part of the clinical management for patients starting this care regimen.
A clinical observation of a 75-year-old patient showed no amyloid protein on a brain PET scan after 18 months of infusion therapy. This outcome follows baseline testing that confirmed initial amyloid protein buildup in the brain.
The players
Baptist Health
The medical provider where the patient received infusion treatment and imaging services.
FDA
The federal agency responsible for evaluating and approving therapies for early-stage Alzheimer's disease.
The details
The treatment involves infusion medications like lecanemab and donanemab, which are designed to remove amyloid protein plaques from the brain. Over the course of the 18-month infusion regimen, these therapies target the underlying protein accumulation associated with early-stage Alzheimer's. The process is monitored by PET scans to confirm whether the amyloid has been successfully cleared from the patient's brain tissue.
Timeline
2024: The patient began the infusion treatment program.
June 2026: The follow-up scan revealed no detectable amyloid protein.
Health Landscape
The use of FDA-approved lecanemab and donanemab infusions represents a shift in Alzheimer's care, focusing on direct protein clearance rather than solely symptom management. This case reflects the ongoing clinical application of these therapies in treating patients with early-stage cognitive impairment.
Patients with early-stage cognitive impairment or concerns about amyloid buildup should discuss potential infusion therapies with their neurologist. It is important to ask a physician how imaging, such as PET scans, is used to track the progress and efficacy of Alzheimer's treatment.
The takeaway
The use of infusion therapies to clear amyloid protein marks a significant step in managing early-stage Alzheimer's disease. Patients should maintain regular communication with their clinical team regarding the use of brain imaging to monitor treatment outcomes.
Further reading
For more information on the latest clinical approaches to cognitive health, see our full guide on Alzheimer’s.
Source note: This article includes information reported by KATV.
